Achievements and challenges in the use of metronomics for the treatment of breast cancer
Two interesting therapeutic proposals for cancer treatment emerged at the beginning of the 21st century. The first one was metronomic chemotherapy, which refers to the chronic administration of chemotherapeutic agents, in low doses, without extended drug-free periods. Then, the idea of drug repositi...
Guardado en:
| Autores principales: | Scharovsky, O. Graciela, Rico, María José, Mainetti, Leandro Ernesto, Perroud, Herman A, Rozados, Viviana R. |
|---|---|
| Formato: | article artículo publishedVersion |
| Lenguaje: | Español |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/2133/19359 http://hdl.handle.net/2133/19359 |
| Aporte de: |
Ejemplares similares
-
Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
por: Perroud, Herman A, et al.
Publicado: (2018) -
Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
por: Rico, María José, et al.
Publicado: (2018) -
Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
por: Perroud, Herman A, et al.
Publicado: (2018) -
Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response
por: Perroud, Herman A, et al.
Publicado: (2018) -
Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer
por: Perroud, Herman A, et al.
Publicado: (2018)